OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
CUBT
CURATIVE BIOTECHNOLOGY INC.
Common Stock
0.0098
0.00031
3.27%
0.0079 / 0.01 (1 x 1)
Real-Time Best Bid & Ask: 05:00pm 06/13/2025
Delayed (15 Min) Trade Data: 12:00am 06/13/2025
0.00826
0.00826 - 0.0108
45,210
N/A
Real-Time Level 2 Quote
Bid
Ask
MPID MPID | Bid Price Bid Price | Size Size | Time Time |
|---|---|---|---|
ETRF | 24.90 | >year | |
CDEL | 21.92 | 03/16 | |
MACM | 18.95 | >year | |
NITE | 18.95 | >year | |
CSTI | 18.55 | >year |
MPID MPID | Ask Price Ask Price | Size Size | Time Time |
|---|---|---|---|
INTL | 19.40 | >year | |
NITE | 19.40 | >year | |
MACM | 19.43 | >year | |
MAXM | 20.11 | >year | |
CANT | 22.05 | >year |
Unlock Real-Time quotes For CUBTFind Out More
Trade Data
Date Date | Timestamp Timestamp | Price Price | $ Change $ Change | Volume Volume |
|---|---|---|---|---|
| 06/13/2025 | 13:19:04 | 0.0098 | 0.00 | 20,000 |
| 06/13/2025 | 13:09:21 | 0.0098 | -0.00 | 200 |
| 06/13/2025 | 12:25:12 | 0.0108 | 0.00 | 1,000 |
| 06/13/2025 | 12:23:36 | 0.0097 | 0.00 | 1,000 |
| 06/13/2025 | 12:22:50 | 0.00916 | 0.00 | 1,000 |
News
Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of DirectorsGlobeNewswire | 03/22/2024
Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of DirectorsGlobeNewswire | 01/08/2024
Filings and Disclosure
Company Description
Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three (3) different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform, based on a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease with the goal of being in the clinic in 2025 for a first in human trial of its metformin-based eye drop. The trial will be conducted under a Cooperative Research and Development Agreement (CRADA) with the NEI.
Videos
This company has not added any videos
Pink Current Information
The Company Profile data was verified by the issuer within the previous 6 months.
The company’s transfer agent has verified its outstanding shares directly to OTC Markets.
The Company’s board of directors includes at least two Independent Directors.
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.
Loading...
Symbol
OTCM
Last
51.15
Change
0.15 (0.29%)
Bid
51.15
Ask
51.40
Volume
13900
Time
00:00
